Phase 1 HCC Clinical Trials
42 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 42 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health30 enrolled21 locationsNCT07547553
Recruiting
Phase 1
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Solid TumorsHepatocellular Carcinoma (HCC)Malignant Melanoma+1 more
Chiome Bioscience Inc.66 enrolled5 locationsNCT06636435
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting
Phase 1
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)+1 more
SEED Therapeutics, Inc.171 enrolled6 locationsNCT07197554
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb198 enrolled59 locationsNCT07291076
Recruiting
Phase 1Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Hepatocellular Carcinoma (HCC)Gastric Cancer (GC)+1 more
Shenzhen Xinhe Biomedical48 enrolled2 locationsNCT07594964
Recruiting
Phase 1
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma (HCC)GPC3 Positive Hepatocellular Carcinoma
Guangzhou FineImmune Biotechnology Co., LTD.15 enrolled1 locationNCT07493044
Recruiting
Phase 1
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
Hepatocellular Carcinoma (HCC)
University of Hawaii15 enrolled2 locationsNCT07075120
Recruiting
Phase 1Phase 2
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.590 enrolled13 locationsNCT06726161
Recruiting
Phase 1Phase 2
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Metastatic Liver CancerAdvanced Hepatocellular Carcinoma (HCC)
Beijing Biotech30 enrolled1 locationNCT07500220
Recruiting
Phase 1Phase 2
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
Hepatocellular Carcinoma (HCC)
Yinghua Xu20 enrolled1 locationNCT07495215
Recruiting
Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech246 enrolled51 locationsNCT07176650
Recruiting
Phase 1
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
Unresectable Hepatocellular Carcinoma (HCC)Hepatoma
Suzhou Mednovo Yi Medical Technology Co., Ltd.40 enrolled8 locationsNCT07391839
Recruiting
Phase 1
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
Melanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)CRC (Colorectal Cancer)+1 more
Hefei TG ImmunoPharma Co., Ltd.194 enrolled1 locationNCT07376707
Recruiting
Phase 1
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Breast Cancer MetastaticNeuroendocrine TumorsRenal Cell Carcinoma (RCC)+2 more
SAPU NANO (US) LLC27 enrolled1 locationNCT07369505
Recruiting
Phase 1
A Phase I Study of CREPT-618 in Locally Advanced HCC
Hepatocellular Carcinoma (HCC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences13 enrolled1 locationNCT07364357
Recruiting
Phase 1
IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
HCC
Shanghai Zhongshan Hospital18 enrolled1 locationNCT06757881